Weight loss injections in India: what to know first

Which medicines are used as weight loss injections?

When people search for a weight loss injection, they are almost always talking about one of two prescription molecules: tirzepatide (sold as Mounjaro) and semaglutide. An older daily option, liraglutide, was also studied for weight management. These are not cosmetic quick-fixes or supplements. They are medicines that mimic gut hormones — semaglutide and liraglutide are GLP-1 receptor agonists, while tirzepatide is a dual GIP/GLP-1 receptor agonist — and they influence insulin release, how fast the stomach empties, and appetite ^{[1] [8]}.

If you have ever typed “injection for weight loss” into a search bar, it is worth understanding the mechanism before the marketing. Because these molecules are engineered to last, most are given as a once-weekly injection under the skin using a pen or vial; liraglutide is the once-daily exception. For the biology of the whole class, see our complete guide to GLP-1, and for individual molecules, our guides to Mounjaro (tirzepatide) and semaglutide.

The table below summarises the molecules studied for weight management, their common brand names, how they are given, and their regulatory status. This is factual regulatory and pharmacological information only. It excludes prices, it is not a recommendation, and none of it should be read as advice to buy or use anything.

Brand names are given only to help you orient yourself; exact indications, brands and availability differ and can change over time. What does not change is that in India all of these are Schedule H1 prescription-only medicines ^[10]. Whether any of them suits a given person is a clinical decision made by a registered medical practitioner after a consultation — never by a website, an advertisement, or the person themselves.

Who is evaluated for weight loss injections?

Who is evaluated is a clinical decision, not a self-assessment: no article can tell you whether one of these injections is right for you, and MensMD does not decide that. What we can share is the regulatory framing that describes the populations these medicines were approved and studied for — the starting point for a doctor's assessment, not a self-qualification checklist.

The clearest attributed reference point is the US FDA label for tirzepatide (Zepbound), which indicates it for adults with a body-mass index (BMI) of at least 30, or at least 27 when accompanied by a weight-related comorbid condition ^[8]. Those cut-offs describe who was studied and approved — they are context for a conversation, not a verdict.

India is a special case, because the thresholds for excess weight are lower than in the West. A 2024 consensus for Asian Indians adopted a two-stage definition of obesity that flags increased adiposity from a BMI above 23 kg/m² — well below the global obesity cut-off of 30 — and adds waist circumference, waist-to-height ratio and functional or comorbidity criteria to identify more advanced disease ^[13]. This matters because a number that looks unremarkable on a Western chart can already signal metabolic risk in an Indian body.

In practice, a registered medical practitioner weighs your full picture — BMI and fat distribution, blood sugar and other lab results, existing conditions, other medicines, family history, and the label contraindications — before deciding whether treatment is appropriate at all, and if so, which one. If in-person examination or further testing is needed first, that judgment stands. The appropriate next step is a weight-management assessment and a consultation, not a purchase.

How much weight did people lose in trials?

In randomised controlled trials these injections produced substantial average weight change — the size of that evidence base is the reason they are discussed so widely. Below are the headline, attributed findings from the primary trials in our reference list. Every one of these numbers is an average from a specific studied population under supervised trial conditions — and these cohorts were largely non-Indian, so they describe what researchers observed, not what any individual should expect.

The dangers of unsupervised use

The demand for these injections has created a grey market, and it is genuinely dangerous. Searching “weight loss injections near me” and buying from whoever will sell without a valid prescription puts you on the wrong side of both the law and basic safety.

Start with the law. In India, tirzepatide and semaglutide are Schedule H1 prescription-only drugs, and advertising or promoting them — including through “social media doctors” and influencer posts — is illegal under the Drugs and Cosmetics Act, 1940 and its Rules, 1945. Penalties run up to Rs 5 lakh, licence revocation or imprisonment ^[10]. If a seller is advertising a prescription weight loss injection to you directly, that is itself a red flag.

Then the counterfeits. In June 2024, the World Health Organization issued an alert about falsified Ozempic (semaglutide) after three falsified batches were found in regulated supply chains in Brazil, the UK and the US; injecting a product of unknown origin risks incorrect dosage, contamination and life-threatening harm ^[9]. The danger is straightforward: outside the licensed pharmacy channel, you cannot know what is actually in the pen.

Finally, the medicine itself demands screening. The US FDA label for tirzepatide carries a boxed warning — the strongest type — for thyroid C-cell tumours, and contraindicates use in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[8]. Indian reporting on the grey market specifically names pancreatitis and thyroid cancer among the risks that make unsupervised use hazardous ^[10]. A doctor exists precisely to check for these before you ever take a first dose — and no online seller can do that.

What does a doctor-led program involve?

A doctor-led weight-management program moves, broadly, from assessment to labs to consultation to ongoing monitoring. It is a sequence of clinical steps — looking nothing like a one-click purchase — and every treatment decision inside it belongs to a registered medical practitioner.

Cost & access realities in India

India has a large metabolic-disease burden, which is why interest in these injections is so high here. The national ICMR-INDIAB study (n=113,043 adults) estimated that 28.6% of Indian adults have generalised obesity and 39.5% have abdominal obesity ^[14]. Against that backdrop, demand has run well ahead of careful, supervised use.

On access, the landscape shifted quickly. Mounjaro (tirzepatide) was launched in India in 2025 for chronic weight management and type 2 diabetes ^[11], and the expiry of Novo Nordisk's Indian semaglutide patent around March 2026 opened the door to generic semaglutide brands from several domestic manufacturers, including Dr Reddy's, Zydus, Alkem, Sun Pharma and Glenmark ^[12]. More brands generally means wider availability, but availability is not the same as suitability.

Cost is a real consideration, and an honest one. These are premium, largely out-of-pocket therapies, and because the trial benefit accrues while treatment continues, they represent an ongoing commitment rather than a one-off spend. We do not publish prices for prescription medicines, and the practical realities of affordability, supply and long-term suitability are exactly the kind of thing to work through with a doctor — not to gamble on with an anonymous seller. The right first move is a weight-management assessment and a consultation, so any decision is made on medical grounds by someone accountable for your care.

Frequently asked questions